

## Title (en)

PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF

## Title (de)

PEPTID-INHIBITOREN DER FOKALEN ADHÄSIONSKINASEAKTIVITÄT UND DEREN VERWENDUNGEN

## Title (fr)

INHIBITEURS PEPTIDIQUES DE L'ACTIVITÉ DE KINASE D'ADHÉRENCE FOCALE ET UTILISATION ASSOCIÉES

## Publication

**EP 4021475 A4 20240214 (EN)**

## Application

**EP 20858603 A 20200831**

## Priority

- US 201962894726 P 20190831
- US 2020048827 W 20200831

## Abstract (en)

[origin: WO2021042064A1] This disclosure provides peptides which have an affinity for the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK). In particular, the peptides are modified and derived from the sequence of the LD2 alpha helical domain of paxillin (e.g., LD2 peptides), the LD4 domain of paxillin (e.g., LD4 peptides), and CD8 peptides. These peptides are capable of blocking an interaction between paxillin and FAK, thereby inhibiting FAK activity related to FAK-paxillin interaction. The invention further provides uses for such peptides as therapeutics for the treatment of cancer and other diseases characterized with FAK activity and/or expression (e.g., fibrosis).

## IPC 8 full level

**A61K 38/00** (2006.01); **A61K 38/10** (2006.01); **A61K 38/12** (2006.01); **A61K 47/64** (2017.01); **A61P 35/00** (2006.01); **C07K 14/47** (2006.01); **C07K 19/00** (2006.01); **C12N 9/12** (2006.01)

## CPC (source: EP KR US)

**A61K 38/00** (2013.01 - KR); **A61K 38/12** (2013.01 - US); **A61K 45/06** (2013.01 - US); **A61K 47/542** (2017.07 - EP); **A61K 47/545** (2017.07 - EP); **A61K 47/55** (2017.07 - EP); **A61K 47/60** (2017.07 - US); **A61K 47/64** (2017.07 - EP); **A61K 47/641** (2017.07 - EP); **A61K 49/0041** (2013.01 - US); **A61P 35/00** (2017.12 - EP KR); **C07K 7/64** (2013.01 - KR US); **C07K 14/4703** (2013.01 - EP); **C07K 14/4747** (2013.01 - EP); **C07K 14/705** (2013.01 - EP); **C07K 19/00** (2013.01 - EP); **C12N 9/1205** (2013.01 - EP); **C12Y 207/10002** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **C07K 23/19/00** (2013.01 - EP)

## Citation (search report)

- [Y] WO 2019157131 A1 20190815 - DANA FARBER CANCER INST INC [US]
- [A] US 2009239850 A1 20090924 - CANCER WILLIAM G [US], et al
- [Y] US 2019202862 A1 20190704 - VERDINE GREGORY L [US], et al
- [XYI] NOTT ET AL: "Synthesis and Characterization of LD2 Peptide Analogs to Inhibit Focal Adhesion Kinase in Cancer", 31 May 2019 (2019-05-31), XP009528178, Retrieved from the Internet <URL:https://repository.asu.edu/items/52596>
- [A] NOCULA-LUGOWSKA MALGORZATA ET AL: "Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin", JOURNAL OF MOLECULAR BIOLOGY, vol. 427, no. 15, 16 June 2015 (2015-06-16), United Kingdom, pages 2532 - 2547, XP055813834, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2015.06.004
- [A] HOELLERER MARIA K. ET AL: "Molecular Recognition of Paxillin LD Motifs by the Focal Adhesion Targeting Domain", STRUCTURE, vol. 11, no. 10, 3 October 2003 (2003-10-03), AMSTERDAM, NL, pages 1207 - 1217, XP055813847, ISSN: 0969-2126, DOI: 10.1016/j.str.2003.08.010
- See references of WO 2021042064A1

## Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

## DOCDB simple family (publication)

**WO 2021042064 A1 20210304**; AU 2020335937 A1 20220324; CA 3148882 A1 20210304; EP 4021475 A1 20220706; EP 4021475 A4 20240214; JP 2022546497 A 20221104; KR 20220054352 A 20220502; US 2022306692 A1 20220929

## DOCDB simple family (application)

**US 2020048827 W 20200831**; AU 2020335937 A 20200831; CA 3148882 A 20200831; EP 20858603 A 20200831; JP 2022513631 A 20200831; KR 20227009927 A 20200831; US 202017638930 A 20200831